Yoga-based rehabilitation improved symptoms and daily function in heart failure
A structured yoga-based cardiac rehabilitation program improved quality of life and physical function in adults living with heart failure with reduced ejection fraction, even though it did not significantly lower the combined risk of death, hospitalization or stroke. In a large multicenter trial conducted across India, the intervention produced a clear symptomatic benefit by three months, with participants reporting better health status and walking farther on a six-minute test than those receiving enhanced standard care.
The pattern is clinically familiar and important. In advanced heart failure, patients often live with breathlessness, fatigue, and a shrinking ability to carry out routine activities long before hard outcomes move. A rehabilitation approach that improves how patients feel and function can still matter in a condition where congestion, low exercise tolerance, and repeated decompensation dominate day-to-day life. For many people, the ability to walk farther, climb stairs with less difficulty, or simply feel less constrained by symptoms changes how treatment is experienced at the bedside.
The study enrolled nearly 3,500 adults with heart failure across 16 medical centers in India between April 2023 and December 2025. Women made up 27% of the cohort, the median age was 57 years, and nearly 40% of participants were recruited from inpatient or hospital settings. About half had NYHA class III disease, indicating marked limitation of physical activity. The population also included patients hospitalized with acute decompensated heart failure and those living with chronic disease, a mix that reflects the broad clinical burden of heart failure in routine practice.
A culturally adapted rehab model delivered structured yoga and education
Investigators randomized 3,492 patients with reduced ejection fraction heart failure to one of two strategies. One group received Yoga CaRe, a standardized program that combined tailored health education, goal-based counseling, and a structured set of yoga practices. The program was delivered in 20 supervised sessions over three months, followed by one session every three months through the end of follow-up. The comparison group received enhanced standard care, which included three health education and information sessions over the same initial three-month period plus the same patient booklet used in the yoga arm.
The design reflects a pragmatic attempt to answer a difficult question: can a low-cost, culturally acceptable rehabilitation model fill a gap in settings where traditional cardiac rehab is scarce, expensive, or inaccessible? In India, where between 8 million and 10 million people are living with heart failure and many are younger than patients with heart failure in high-income countries, the need for scalable rehabilitation is especially acute. When hospital systems cannot supply resource-intensive exercise programs to everyone who needs them, a simpler behavioral intervention becomes more than an academic idea. It becomes a potential service model.
Yoga has an intuitive fit in that setting because it can be delivered with limited equipment and can be framed as a low-impact physical activity option for patients who may be reluctant to join conventional exercise programs. The intervention was also delivered by a board-certified yoga and naturopathy practitioner, which may help explain the high participation in supervised sessions and home practice. The trial’s structure suggests an effort to combine lifestyle counseling with a form of movement therapy that patients may actually adopt and sustain.
Quality-of-life gains emerged without a hard-outcome advantage
At three months, the yoga-based rehabilitation group recorded about an 8-point improvement in Minnesota Living with Heart Failure Questionnaire scores compared with enhanced standard care, with lower scores indicating better quality of life. The group also showed better performance on the 6-minute walk distance, covering an average of 25.5 meters more than the comparison group. Health status on the EQ-5D-5L was also better in the yoga arm.
Those changes are not trivial in a disease where reduced cardiac output, peripheral deconditioning, and symptom anxiety reinforce one another. Better functional capacity can reflect more than muscle conditioning. Gentle, structured movement may improve autonomic balance, breathing efficiency, confidence with exertion, and adherence to a healthier routine, all of which are relevant in chronic heart failure. The benefit may be especially meaningful for patients whose lives are defined less by dramatic acute events than by daily limits.
The hard clinical endpoint told a different story. During a median follow-up of 15 months, 364 participants in the yoga group, or 21.0%, experienced the composite of death, hospitalization or stroke, compared with 401 participants, or 22.8%, in the enhanced standard care group. The difference was not statistically significant. In other words, the program improved how participants felt and functioned, but it did not clearly change the short-term trajectory of major adverse events.
What the trial can and cannot claim
The interpretation needs to stay grounded in the trial’s design. Because participants knew whether they were in the yoga program, the intervention could not be blinded, as is true for most cardiac rehabilitation and behavioral trials. The intervention arm also involved far more contact with instructors than the control arm, with 20 supervised sessions versus three education sessions. Extra contact alone can influence engagement, expectations, and self-reported outcomes, so the symptom benefit should not be separated entirely from the delivery model itself.
Even with those limits, the findings are clinically useful. They suggest that a structured yoga-based program can be integrated into heart failure care and may improve quality of life, exercise tolerance, and patient-reported health status in a setting where conventional rehab is difficult to access. The absence of a reduction in death, hospitalization, or stroke does not erase the symptomatic gains; it simply means the intervention should not be sold as a substitute for disease-modifying heart failure therapy or established secondary prevention.
Future work should focus on implementation at scale and on testing the approach in other healthcare settings. Cost-effectiveness data were not yet available, and that will matter for health systems deciding whether to adopt the model broadly. The remaining question is not whether patients can feel better with this kind of program—they can—but how reliably that benefit can be delivered outside a research setting, and whether the same results hold when the intervention is translated into different clinical environments and populations.